TLRY
Tilray Brands, Inc. · Healthcare · Drug Manufacturers - Specialty & Generic
Last
$3.04
−$0.17 (−5.20%) 4:00 PM ET
After hours $3.04 −$0.01 (−0.26%) 2:42 AM ET
Prev close $3.21
Open $3.25
Day high $3.25
Day low $3.03
Volume 2,841,930
Avg vol 4,119,839
Mkt cap
$474.40M
EV/Sales
0.48
P/E ratio
-2.74
FY Revenue
$963.10M
EPS
-1.11
Gross Margin
29.12%
Div yield
0.00%
Sector
Healthcare
AI report sections
TLRY
Tilray Brands, Inc.
Tilray’s share price has staged a sharp multi-month rebound, with the latest close well above short-term moving averages and near the upper end of recent breakout zones. At the same time, fundamentals remain heavily loss-making with deeply negative margins and free cash flow, creating a notable gap between price momentum and underlying earnings quality. Extremely elevated short interest and short volume ratios indicate substantial positioning risk and the potential for amplified volatility around news and sentiment shifts.
AI summarized at 11:53 PM ET, 2025-12-16
AI summary scores
INTRADAY: 68 SWING: 72 LONG: 28
Volume vs average
Intraday (cumulative)
−20% (Below avg)
Vol/Avg: 0.80×
RSI
28.04 (Oversold)
Oversold (<30)
MACD momentum
Intraday
+0.00 (Strong)
MACD: -0.00 Signal: -0.00
Short-Term
-0.05 (Weak)
MACD: -0.26 Signal: -0.21
Long-Term
-0.07 (Weak)
MACD: -0.29 Signal: -0.22
Intraday trend score 24.04

Latest news

TLRY 12 articles Positive: 5 Neutral: 3 Negative: 4
Positive The Motley Fool • Sara Appino
Canopy Growth vs. Tilray Brands: Which Cannabis Stock Is a Better Buy in 2026?

The article compares two major cannabis companies navigating industry challenges. Canopy Growth focuses on premium Canadian cannabis and European medical sales but faces internal control weaknesses and significant losses. Tilray Brands has diversified into beverages and international markets, posting record Q1 revenue of $257M with improving margins. The author recommends Tilray as the better choice due to its larger scale, diversified revenue streams, and clearer path to profitability, though both stocks remain risky investments in a volatile industry.

CGC TLRY cannabis stocks Canopy Growth Tilray Brands profitability revenue growth diversification
Sentiment note

Company demonstrates stronger fundamentals with record Q1 revenue ($257M, +23% YoY), faster gross profit growth, and BrewDog acquisition turning profitable. Diversified revenue streams and clearer path to profitability make it the recommended choice, though still operating at a loss overall.

Positive GlobeNewswire Inc. • Na
SweetWater Brewing Gives Fans the Chance to Win Tickets to Their Dream Show at AEG Venues Across Georgia

SweetWater Brewing, a craft brewery brand by Tilray Brands, launched a concert sweepstakes giving fans 21+ the chance to win tickets to 2026-2027 AEG concerts at select Georgia venues including Georgia Theatre, The Eastern, Variety Playhouse, and Terminal West. Two winners will be selected with prizes valued at approximately $1,200 each, including concert tickets and travel gift cards. The sweepstakes runs through December 31, 2026.

TLRY sweepstakes concert tickets SweetWater Brewing AEG venues Georgia live music craft brewery
Sentiment note

The company is expanding its brand engagement and marketing reach through a high-value consumer promotion that strengthens brand loyalty and connects SweetWater Brewing with live entertainment experiences, demonstrating active brand investment and consumer-focused initiatives.

Negative The Motley Fool • David Jagielski, Cpa
3 Huge Red Flags From Tilray's Q1 Earnings Report

Tilray Brands reported Q1 fiscal 2027 results with concerning fundamentals despite revenue growth. The company's cash burn spiked to $16.5 million (up from $1.3 million year-over-year), core cannabis revenue declined 13%, and operating expenses surged 83%. While top-line growth was driven by acquisitions like BrewDog, organic cannabis business weakness and ballooning costs suggest the stock faces continued headwinds.

TLRY CGC ACB cannabis stocks earnings report cash burn acquisitions organic growth
Sentiment note

Significant cash burn increase ($16.5M vs $1.3M YoY), declining core cannabis revenue (-13%), and operating expenses growing faster than revenue (+83% vs +23% top-line growth) indicate deteriorating financial health and unsustainable business model. The company relies on acquisitions to mask organic weakness rather than genuine growth.

Neutral The Motley Fool • Sarah Sidlow
Canopy Growth vs. Tilray Brands: Which Healthcare Stock Is a Better Buy in 2026?

Canopy Growth and Tilray Brands represent diverging strategies in the cannabis industry. Canopy pursues a lean, brand-focused model with emphasis on U.S. expansion, while Tilray has diversified into craft beverages and wellness products. Both companies reported significant net losses in FY 2026 despite revenue growth, with Tilray showing better financial metrics (higher revenue, lower debt-to-equity ratio, higher gross margin) but greater business complexity. The article suggests Tilray may appeal to diversification-focused investors, while Canopy attracts those betting on pure cannabis growth, though both carry substantial risks.

CGC TLRY cannabis industry U.S. legalization diversification strategy financial losses craft beverages regulatory uncertainty
Sentiment note

Company demonstrates stronger revenue growth (11% YoY, $915.5M) and better financial health metrics (lower debt-to-equity at 0.2x, higher gross margin at 26.82%) compared to Canopy. However, it still reports substantial net losses (-$105.2M), negative free cash flow (-$98.6M), and faces integration risks from acquisitions. Diversification into beverages reduces cannabis dependency but adds complexity.

Negative Zacks Investment Research • Na
CRON Stock Rises 17% in Three Months: Time to Buy the Dip or Cash Out?

Cronos Group shares rose 17% over three months following better-than-expected Q2 2026 results, with first-half revenues up 49% to $98.2 million driven by Canadian market share gains and international expansion. However, the company faces challenges including potentially unsustainable margin improvements, an Israeli anti-dumping investigation, and intensifying European competition from rivals like Village Farms and Tilray. Analysts maintain a cautious stance with unchanged earnings estimates.

CRON VFF TLRY cannabis earnings revenue growth international expansion competition
Sentiment note

Identified as another competitive threat strengthening its international medical cannabis business across multiple European markets (Germany, UK, Poland, Italy), with established European presence that could intensify competition against Cronos' expansion efforts.

Negative Zacks Investment Research • Na
Tilray Brands, Inc. (TLRY) Reports Q1 Loss, Misses Revenue Estimates

Tilray Brands reported a quarterly loss of $0.32 per share, significantly worse than the consensus estimate of $0.19, representing a -68.42% earnings surprise. The company also missed revenue expectations, posting $257.15 million versus the estimate of $262.35 million. With unfavorable estimate revisions, Tilray received a Zacks Rank #5 (Strong Sell) rating and has underperformed the S&P 500 by 58.9% year-to-date.

TLRY SYK earnings surprise loss per share revenue miss Zacks Rank medical products industry stock underperformance
Sentiment note

Company significantly missed EPS expectations with a loss of $0.32 vs. consensus of $0.19 (-68.42% surprise), missed revenue targets, has not surpassed consensus estimates in four quarters, received a Zacks Rank #5 (Strong Sell) rating, and has underperformed the market by 58.9% year-to-date.

Negative The Motley Fool • David Jagielski, Cpa
Tilray Brands: Is the Stock a Buy at Less Than $4?

Tilray Brands stock has crashed 60% this year and trades below $4, down 84% from its 52-week high. Despite record revenue of $915 million, the company posted a net loss of $105 million and burned $69 million in cash. The analyst recommends avoiding the stock due to poor growth prospects, a highly competitive Canadian market, and a questionable pivot to beverages that doesn't address fundamental business challenges.

TLRY cannabis stocks marijuana legalization stock valuation cash burn beverage acquisitions speculative investment
Sentiment note

The article presents a bearish outlook citing weak growth prospects, significant net losses despite record revenue, ongoing cash burn of $69 million annually, a highly competitive Canadian market with thin margins, and a questionable diversification strategy into beverages. The analyst explicitly recommends avoiding the stock and suggests it could fall further.

Positive Zacks Investment Research • Na
VFF Stock Up 49% in Three Months: Is the Rally Sustainable?

Village Farms International (VFF) shares have surged 49% in three months, driven by 15% cannabis sales growth and expanding 51% gross margins, primarily from strong European exports led by Germany. However, the company faces increasing competition from Tilray and Canopy Growth in European markets, pricing pressure from rising industry supply, and heavy dependence on Germany for export growth. While the company holds a Zacks Rank #3 (Hold), investors should await evidence of successful market diversification before committing to longer-term positions.

VFF TLRY CGC cannabis international exports Europe Germany gross margin expansion
Sentiment note

Tilray is actively expanding its European medical cannabis presence, including Germany where it launched a premium brand and expanded cultivation/distribution capabilities. The company is increasing global production capacity to capitalize on rising international demand, positioning it as a strong competitor in the growing European market.

Neutral The Motley Fool • David Jagielski, Cpa
Tilray Brands Has Lost More Than Half of Its Value in 2026, but Here's the Bullish Case for Taking a Chance on This Highly Risky Stock

Tilray Brands has lost over 50% of its value in 2026 and is down 95% over five years, making it a highly risky investment. However, the bullish case centers on potential U.S. marijuana legalization, which could trigger significant stock appreciation even before full legalization occurs. The company has diversified into beverages and alcohol to position itself for future U.S. market entry. While the stock could surge on legalization discussions similar to Canada's 2018 experience, investors should be aware of substantial risks and uncertainty.

TLRY ACB CGC marijuana legalization cannabis stocks U.S. pot market high-risk investment stock volatility
Sentiment note

The article presents a balanced view acknowledging both significant downside risks (95% decline over 5 years, unprofitability, high volatility) and potential upside from U.S. marijuana legalization. The author explicitly states it's not suitable for most investors and emphasizes uncertainty, while noting a legitimate bullish case exists for high-risk investors.

Neutral The Motley Fool • Reuben Gregg Brewer
Tilray Trades Below $5 With Record Fiscal Revenue on the Books. What's Holding the Stock Back?

Tilray Brands has achieved record fiscal 2026 revenues of $915 million and successfully diversified beyond marijuana into beverages and wellness products, but the stock remains depressed below $5 due to continued unprofitability (losing $1.09 per share in fiscal 2026) and its tiny $600 million market cap relative to established consumer staples competitors. The company is only suitable for aggressive investors until it demonstrates sustainable profitability.

TLRY KO Tilray Brands marijuana sector business diversification consumer staples profitability record revenue
Sentiment note

While the company shows positive operational progress with record revenues and successful diversification into beverages and wellness, persistent losses and a tiny market cap relative to competitors prevent profitability. The stock is appropriate only for risk-tolerant investors until earnings turn positive, making it neither a clear buy nor sell.

Positive The Motley Fool • Reuben Gregg Brewer
Should You Buy Canopy Growth Stock on the Rebound?

Canopy Growth showed strong Q1 fiscal 2027 results with 13% revenue growth across all business divisions, improved gross margins, and significantly reduced losses. However, the company remains a penny stock with over 400% share dilution in three years. While the business turnaround is promising, the article recommends most investors monitor rather than buy, citing the sector's history of underperformance and the need to see sustained improvement before investing.

CGC TLRY ACB cannabis industry marijuana stocks penny stock business consolidation share dilution
Sentiment note

Mentioned as actively consolidating the marijuana sector through its acquisition of Brew Dog, expanding its beverage business. The article notes this as part of a potentially important industry consolidation trend.

Positive GlobeNewswire Inc. • Na
By Popular Demand: Tilray Beverages Makes Popsicle Hard Firecracker a Permanent Flavor

Tilray Brands and The Magnum Ice Cream Company announced that Popsicle Hard Firecracker, a limited-edition nostalgic red-white-and-blue flavored hard beverage, will transition to a permanent year-round offering following overwhelming consumer demand. The flavor joins existing year-round offerings including Hard Cherry, Hard Grape, and Hard Orange in the Popsicle Hard portfolio.

TLRY MICC Popsicle Hard limited-edition to permanent consumer demand flavored malt beverage product expansion nostalgic flavor
Sentiment note

The company successfully converted a limited-edition product into a permanent offering based on strong consumer demand, demonstrating successful product-market fit and brand strength. This expansion indicates growing consumer interest and revenue potential in their beverage portfolio.

News and sentiment labels describe article tone and are provided for research purposes only. They are not trading recommendations or forecasts.
Trade Ranks, LLC is not a registered investment adviser or broker-dealer. All rankings and AI reports are for informational and educational purposes only and are not personalized advice. Investing involves risk. Policy Portal